NZ730773A - Treatment of fibrodysplasia ossificans progressiva - Google Patents
Treatment of fibrodysplasia ossificans progressivaInfo
- Publication number
- NZ730773A NZ730773A NZ730773A NZ73077315A NZ730773A NZ 730773 A NZ730773 A NZ 730773A NZ 730773 A NZ730773 A NZ 730773A NZ 73077315 A NZ73077315 A NZ 73077315A NZ 730773 A NZ730773 A NZ 730773A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- nos
- antibody
- light chain
- cdrs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049869P | 2014-09-12 | 2014-09-12 | |
| US201562141775P | 2015-04-01 | 2015-04-01 | |
| PCT/US2015/000100 WO2016039796A2 (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ730773A true NZ730773A (en) | 2022-07-01 |
Family
ID=54207748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ730773A NZ730773A (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20160075772A1 (enExample) |
| EP (2) | EP3191512B1 (enExample) |
| JP (1) | JP6560341B2 (enExample) |
| KR (1) | KR102564079B1 (enExample) |
| CN (1) | CN107106648B (enExample) |
| AU (1) | AU2015315829B2 (enExample) |
| CA (1) | CA2960950C (enExample) |
| CL (2) | CL2017000603A1 (enExample) |
| CY (1) | CY1122188T1 (enExample) |
| DK (1) | DK3191512T3 (enExample) |
| ES (1) | ES2739605T3 (enExample) |
| HR (1) | HRP20191929T1 (enExample) |
| HU (1) | HUE046558T2 (enExample) |
| IL (1) | IL251063B (enExample) |
| LT (1) | LT3191512T (enExample) |
| MA (1) | MA40621B1 (enExample) |
| ME (1) | ME03541B (enExample) |
| MX (1) | MX382026B (enExample) |
| MY (1) | MY179654A (enExample) |
| NZ (1) | NZ730773A (enExample) |
| PL (1) | PL3191512T3 (enExample) |
| PT (1) | PT3191512T (enExample) |
| RS (1) | RS59412B1 (enExample) |
| SG (2) | SG11201701913SA (enExample) |
| SI (1) | SI3191512T1 (enExample) |
| SM (1) | SMT201900584T1 (enExample) |
| TW (1) | TWI688402B (enExample) |
| WO (1) | WO2016039796A2 (enExample) |
| ZA (1) | ZA201702112B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2780368T3 (pl) | 2011-11-14 | 2018-06-29 | Regeneron Pharmaceuticals, Inc. | Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| MX2017013520A (es) | 2015-04-22 | 2018-05-22 | Alivegen Usa Inc | Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular. |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| EP3415527B1 (de) * | 2017-06-14 | 2025-12-10 | Kymab Ltd. | Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen |
| JP7579706B2 (ja) | 2018-03-01 | 2024-11-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 体組成を変更するための方法 |
| CN111836643A (zh) * | 2018-03-05 | 2020-10-27 | 学校法人埼玉医科大学 | 用于治疗或预防异位骨化的药物组合物 |
| WO2019195796A1 (en) | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
| CA3099441A1 (en) | 2018-06-13 | 2019-12-19 | Regeneron Pharmaceuticals, Inc. | A rodent model of fibrodysplasia ossificans progressiva |
| US20210214456A1 (en) | 2018-06-13 | 2021-07-15 | Kymab Limited | Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EA202190418A1 (ru) * | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение в лечении прогрессирующей оссифицирующей фибродисплазии |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP7512272B2 (ja) * | 2018-10-23 | 2024-07-08 | ケロス セラピューティクス インコーポレイテッド | Ａｌｋ２抗体及びその使用方法 |
| MX2021007394A (es) * | 2018-12-18 | 2021-07-15 | Regeneron Pharma | Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. |
| EP4087652A1 (en) * | 2020-01-08 | 2022-11-16 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| WO2021142260A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
| US12472253B2 (en) * | 2020-06-18 | 2025-11-18 | Regeneron Pharmaceuticals, Inc. | Activin a antibody formulations and methods of use thereof |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| MX2023005565A (es) * | 2020-11-11 | 2024-02-23 | Hq Han | Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos. |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL310810A (en) * | 2021-09-03 | 2024-04-01 | Laekna Therapeutics Shanghai Co Ltd | Anti-ACVR2A antibodies and uses thereof |
| WO2024234869A1 (en) * | 2023-05-15 | 2024-11-21 | Immunecare Biopharmaceuticals (Shanghai) Co., Ltd. | Recombinant fusion protein for treatment of pulmonary hypertension |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CN100405399C (zh) | 1999-02-05 | 2008-07-23 | 三星电子株式会社 | 图像纹理恢复方法及其装置 |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| DK1709081T3 (da) | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8859752B2 (en) * | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| JP2010502220A (ja) * | 2006-09-05 | 2010-01-28 | メダレックス インコーポレーティッド | 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法 |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TW201907946A (zh) * | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| JP5270913B2 (ja) | 2007-12-26 | 2013-08-21 | サンゴバン・ティーエム株式会社 | 高電気抵抗高ジルコニア鋳造耐火物 |
| CA2718403A1 (en) * | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| WO2009137075A1 (en) | 2008-05-06 | 2009-11-12 | Acceleron Pharma Inc. | Anti-activin antibodies and uses for promoting bone growth |
| EP2583692A4 (en) * | 2010-06-18 | 2014-11-26 | Lsip Llc | HEMMER OF THE EXPRESSION OF DOMINANT ALLELES |
| WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
| PL2780368T3 (pl) * | 2011-11-14 | 2018-06-29 | Regeneron Pharmaceuticals, Inc. | Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A |
| WO2014051109A1 (ja) | 2012-09-28 | 2014-04-03 | 協和発酵キリン株式会社 | 抗ヒトｂｍｐ９抗体および該抗体を有効成分とする異所性骨化疾患の治療剤 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| JP6601687B2 (ja) | 2014-03-31 | 2019-11-06 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| AR103675A1 (es) * | 2015-02-13 | 2017-05-24 | Sorrento Therapeutics Inc | Anticuerpos anti-ctla4 terapéuticos |
| US20160319009A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
-
2015
- 2015-09-10 US US14/850,844 patent/US20160075772A1/en not_active Abandoned
- 2015-09-11 TW TW104130079A patent/TWI688402B/zh active
- 2015-09-14 HU HUE15775835A patent/HUE046558T2/hu unknown
- 2015-09-14 MA MA40621A patent/MA40621B1/fr unknown
- 2015-09-14 IL IL251063A patent/IL251063B/en unknown
- 2015-09-14 ES ES15775835T patent/ES2739605T3/es active Active
- 2015-09-14 DK DK15775835.0T patent/DK3191512T3/da active
- 2015-09-14 SG SG11201701913SA patent/SG11201701913SA/en unknown
- 2015-09-14 AU AU2015315829A patent/AU2015315829B2/en active Active
- 2015-09-14 WO PCT/US2015/000100 patent/WO2016039796A2/en not_active Ceased
- 2015-09-14 JP JP2017513774A patent/JP6560341B2/ja active Active
- 2015-09-14 ME MEP-2019-279A patent/ME03541B/me unknown
- 2015-09-14 SI SI201530852T patent/SI3191512T1/sl unknown
- 2015-09-14 PT PT15775835T patent/PT3191512T/pt unknown
- 2015-09-14 EP EP15775835.0A patent/EP3191512B1/en active Active
- 2015-09-14 LT LTEP15775835.0T patent/LT3191512T/lt unknown
- 2015-09-14 KR KR1020177009673A patent/KR102564079B1/ko active Active
- 2015-09-14 SM SM20190584T patent/SMT201900584T1/it unknown
- 2015-09-14 CA CA2960950A patent/CA2960950C/en active Active
- 2015-09-14 PL PL15775835T patent/PL3191512T3/pl unknown
- 2015-09-14 SG SG10201902175RA patent/SG10201902175RA/en unknown
- 2015-09-14 MY MYPI2017700819A patent/MY179654A/en unknown
- 2015-09-14 EP EP19177741.6A patent/EP3604335A1/en not_active Withdrawn
- 2015-09-14 MX MX2017003175A patent/MX382026B/es unknown
- 2015-09-14 CN CN201580049029.1A patent/CN107106648B/zh active Active
- 2015-09-14 NZ NZ730773A patent/NZ730773A/en unknown
- 2015-09-14 HR HRP20191929TT patent/HRP20191929T1/hr unknown
- 2015-09-14 RS RSP20191331 patent/RS59412B1/sr unknown
-
2017
- 2017-03-10 CL CL2017000603A patent/CL2017000603A1/es unknown
- 2017-03-27 ZA ZA2017/02112A patent/ZA201702112B/en unknown
- 2017-08-28 US US15/688,740 patent/US20180111983A1/en not_active Abandoned
-
2018
- 2018-10-17 CL CL2018002962A patent/CL2018002962A1/es unknown
-
2019
- 2019-09-17 CY CY20191100972T patent/CY1122188T1/el unknown
- 2019-09-23 US US16/579,126 patent/US11407822B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ730773A (en) | Treatment of fibrodysplasia ossificans progressiva | |
| ECSP099683A (es) | Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos. | |
| MX2021008888A (es) | Anticuerpos anti-tau humanizados. | |
| MX2021003436A (es) | Anticuerpos humanos para pd-1. | |
| MX2018014950A (es) | Terapia de combinacion. | |
| MX2020002880A (es) | Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). | |
| EA201170157A1 (ru) | Notch-связывающие агенты и антагонисты и способы их применения | |
| PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| EA201791171A1 (ru) | Антитела к tigit | |
| WO2008105886A3 (en) | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| MXPA06012601A (es) | Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos. | |
| NZ591471A (en) | Antibodies to ccr2 | |
| WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| MX2022006147A (es) | Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1. | |
| CN110291105B (zh) | 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗 | |
| Mazor et al. | Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1 | |
| US20180030124A1 (en) | Methods and compositions for enhancing anti-ssea4 immunotherapy | |
| EA202190495A1 (ru) | Антитела против pd-l1 человека | |
| EP3091031A1 (en) | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor | |
| JP2009502206A (ja) | 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療 | |
| WO2015191610A3 (en) | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways | |
| Ford | Sizing Up the Competition: Fc-Mediated Effector Functions of Immune Therapeutics Impaired During Chronic Viral Infection | |
| PH12017500470A1 (en) | Treatment of fibrodysplasia ossificans progressiva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2024 BY ANAQUA SERVICES Effective date: 20230823 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2025 BY ANAQUA SERVICES Effective date: 20240820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2026 BY ANAQUA SERVICES Effective date: 20250820 |